2
|
Abstract
Human fatigue is an important factor in transportation safety and a major causal factor of accidents. Employers play a vital role in minimizing fatigue-related risk, and are legally liable for damages arising from failure to address the risk. By taking an active role as stakeholders in transportation safety, employers not only reduce their risk of adverse safety events and limit their legal liability but may also benefit from improvements in productivity, morale, and health care expenditures. Employers should focus on reducing fatigue-related risk, with ongoing support from sleep safety research.
Collapse
Affiliation(s)
- David Rainey
- Occupational Medicine Residency, Harvard Medical School, Harvard TH Chan School of Public Health, Boston, MA, USA; Cambridge Health Alliance Occupational Health, 5 Middlesex Avenue, Somerville, MA 02145, USA
| | - Michael A Parenteau
- Occupational and Environmental Medicine Residency, Harvard T.H. Chan School of Public Health, 665 Huntington Avenue, Building 1, Room 1406, Boston, MA 02115, USA
| | - Stefanos N Kales
- Occupational Medicine Residency, Harvard Medical School, Harvard TH Chan School of Public Health, Boston, MA, USA; The Cambridge Health Alliance - Occupational Medicine, Macht Building Suite 427, 1493 Cambridge Street, Cambridge, MA 02139, USA.
| |
Collapse
|
3
|
Peršolja M, Mišmaš A, Jurdana M. Povezava med neprespanostjo in delazmožnostjo zaposlenih v zdravstveni negi. OBZORNIK ZDRAVSTVENE NEGE 2018. [DOI: 10.14528/snr.2018.52.1.186] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Uvod: Spanje je aktivni proces, ki pomembno vpliva na kakovost delovnega življenja. V ta namen je bila izvedena raziskava o odnosu med neprespanostjo in delazmožnostjo zaposlenih v zdravstveni negi.Metode: V kvantitativni opisni raziskavi so bili v letih 2014 in 2015 obravnavani zaposleni iz ene splošne bolnišnice in dveh domov upokojencev v Sloveniji. Z enostavnim slučajnostnim izborom je bilo v stratificiran vzorec vključenih 21,26 % (n = 81) v zdravstveni negi zaposlenih žensk iz teh treh zavodov. Podatki, pridobljeni z anketo (Cronbach α = 0,624), so bili analizirani z deskriptivno statistiko in s korelacijsko analizo.Rezultati: Večina anketirank opravlja od tri do sedem nočnih izmen mesečno (x = 3,76, s = 2,51). Vse anketiranke imajo težave z nespečnostjo (n = 81, 100 %), večina jih s težavo ostaja budnih na delovnem mestu (n = 52, 64,2 %). Težave z budnostjo na delovnem mestu se povezujejo s slabšim splošnim počutjem (r = 0,236, p = 0,034) in so pogostejše ob večjem številu nočnih izmen v mesecu (r = −0,322, p = 0,003). Anketiranke so mnenja, da neprespanost povečuje verjetnost napak pri delu (n = 60, 74,1 %), upočasnjuje hitrost odzivanja na nepričakovane urgentne situacije na delovnem mestu (n = 58, 71,6 %) ter slabo vpliva na njihovo komunikacijo s pacienti (n = 48, 59,2 %).Diskusija in zaključek: Podobno kot druge tuje raziskave o zaposlenih v zdravstveni negi tudi ta potrjuje, da se neprespanost zaradi nočnega dela povezuje s slabšim počutjem, utrujenostjo in zmanjšano delazmožnostjo.
Collapse
|
5
|
Wong ITY, Chandran V, Li S, Gladman DD. Sleep Disturbance in Psoriatic Disease: Prevalence and Associated Factors. J Rheumatol 2017; 44:1369-1374. [PMID: 28620064 DOI: 10.3899/jrheum.161330] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/10/2017] [Indexed: 02/06/2023]
Abstract
OBJECTIVE We aimed to determine the prevalence and quality of sleep in patients with psoriatic arthritis (PsA) and those with psoriasis without PsA (PsC) followed in the same center, to identify factors associated with sleep disturbance, and to compare findings to those of healthy controls (HC). METHODS The study included 113 PsA [ClASsification for Psoriatic ARthritis (CASPAR) criteria] and 62 PsC (PsA excluded by a rheumatologist) patients and 52 HC. Clinical variables were collected using a standard protocol. The sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI). Other patient-reported outcomes collected included the Health Assessment Questionnaire (HAQ), Dermatology Life Quality Index, EQ-5D, Medical Outcomes Study Short Form-36 survey, patient's global assessment, and the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-fatigue) scale. Statistical analyses included descriptive statistics, Wilcoxon rank-sum test, and linear regression. RESULTS The prevalence of poor sleep quality was 84%, 69%, and 50% in PsA, PsC, and HC, respectively. Total PSQI score was higher in both patients with PsA and patients with PsC compared with HC (p < 0.01) and higher in patients with PsA compared to patients with PsC (p < 0.0001). EQ-5D anxiety component, EQ-5D final, and FACIT-fatigue were independently associated with worse PSQI in patients with PsC and those with PsA (p < 0.05). Actively inflamed (tender or swollen) joints are independently associated with worse PSQI in patients with PsA (p < 0.01). CONCLUSION Patients with psoriatic disease have poor sleep quality. Poor sleep is associated with fatigue, anxiety, and lower EQ-5D. In patients with PsA, poor sleep is associated with active joint inflammation.
Collapse
Affiliation(s)
- Ian T Y Wong
- From the University of British Columbia, Vancouver, British Columbia; the Department of Medicine, Division of Rheumatology, and Department of Laboratory Medicine and Pathobiology, and the Institute of Medical Science, University of Toronto; Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, and Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.,I.T. Wong, BSc (Pharmacy), Medical Student, University of British Columbia; V. Chandran, MBBS, MD, DM, PhD, Assistant Professor, Department of Medicine, Division of Rheumatology, and Department of Laboratory Medicine and Pathobiology, and Institute of Medical Science, University of Toronto, and Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, University Health Network; S. Li, MMath, Biostatistician, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, and Toronto Western Hospital, University Health Network; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director of the Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, and Toronto Western Hospital, University Health Network
| | - Vinod Chandran
- From the University of British Columbia, Vancouver, British Columbia; the Department of Medicine, Division of Rheumatology, and Department of Laboratory Medicine and Pathobiology, and the Institute of Medical Science, University of Toronto; Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, and Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.,I.T. Wong, BSc (Pharmacy), Medical Student, University of British Columbia; V. Chandran, MBBS, MD, DM, PhD, Assistant Professor, Department of Medicine, Division of Rheumatology, and Department of Laboratory Medicine and Pathobiology, and Institute of Medical Science, University of Toronto, and Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, University Health Network; S. Li, MMath, Biostatistician, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, and Toronto Western Hospital, University Health Network; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director of the Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, and Toronto Western Hospital, University Health Network
| | - Suzanne Li
- From the University of British Columbia, Vancouver, British Columbia; the Department of Medicine, Division of Rheumatology, and Department of Laboratory Medicine and Pathobiology, and the Institute of Medical Science, University of Toronto; Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, and Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.,I.T. Wong, BSc (Pharmacy), Medical Student, University of British Columbia; V. Chandran, MBBS, MD, DM, PhD, Assistant Professor, Department of Medicine, Division of Rheumatology, and Department of Laboratory Medicine and Pathobiology, and Institute of Medical Science, University of Toronto, and Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, University Health Network; S. Li, MMath, Biostatistician, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, and Toronto Western Hospital, University Health Network; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director of the Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, and Toronto Western Hospital, University Health Network
| | - Dafna D Gladman
- From the University of British Columbia, Vancouver, British Columbia; the Department of Medicine, Division of Rheumatology, and Department of Laboratory Medicine and Pathobiology, and the Institute of Medical Science, University of Toronto; Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, and Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada. .,I.T. Wong, BSc (Pharmacy), Medical Student, University of British Columbia; V. Chandran, MBBS, MD, DM, PhD, Assistant Professor, Department of Medicine, Division of Rheumatology, and Department of Laboratory Medicine and Pathobiology, and Institute of Medical Science, University of Toronto, and Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, University Health Network; S. Li, MMath, Biostatistician, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, and Toronto Western Hospital, University Health Network; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director of the Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, and Toronto Western Hospital, University Health Network.
| |
Collapse
|